Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-02: A Phase 1/2 Feasibility and Safety Study of CD19-CAR T Cell Immunotherapy for CD19+ Leukemia

Trial Profile

Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-02: A Phase 1/2 Feasibility and Safety Study of CD19-CAR T Cell Immunotherapy for CD19+ Leukemia

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Lisocabtagene-maraleucel (Primary)
  • Indications Acute lymphoblastic leukaemia; Leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PLAT-02
  • Most Recent Events

    • 13 Apr 2017 Results of the phase I part of the study (n=45), published in the Blood
    • 21 Jan 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2020.
    • 06 Dec 2016 Results (n=45) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top